Aptamer Group and PinotBio extend collaboration for the development of Optimer-drug conjugates
Aptamer Group, the developer of novel Optimer binders to enable innovation in the life sciences industry, has extended its collaboration agreement with PinotBio (Gyeonggi-do, Korea), a clinical-stage oncology-focused biotechnology company, to develop four new Optimer-drug conjugates for use as precision chemotherapeutics.
